IBDEI0KL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9082,1,4,0)
 ;;=4^N08.
 ;;^UTILITY(U,$J,358.3,9082,2)
 ;;=^5015569
 ;;^UTILITY(U,$J,358.3,9083,0)
 ;;=C90.00^^69^618^10
 ;;^UTILITY(U,$J,358.3,9083,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9083,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,9083,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,9083,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,9084,0)
 ;;=C90.01^^69^618^9
 ;;^UTILITY(U,$J,358.3,9084,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9084,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,9084,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,9084,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,9085,0)
 ;;=C90.02^^69^618^8
 ;;^UTILITY(U,$J,358.3,9085,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9085,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,9085,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,9085,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,9086,0)
 ;;=E11.29^^69^618^21
 ;;^UTILITY(U,$J,358.3,9086,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9086,1,3,0)
 ;;=3^Type 2 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,9086,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,9086,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,9087,0)
 ;;=E11.21^^69^618^20
 ;;^UTILITY(U,$J,358.3,9087,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9087,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic nephropathy
 ;;^UTILITY(U,$J,358.3,9087,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,9087,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,9088,0)
 ;;=E11.22^^69^618^19
 ;;^UTILITY(U,$J,358.3,9088,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9088,1,3,0)
 ;;=3^Type 2 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,9088,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,9088,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,9089,0)
 ;;=E10.29^^69^618^18
 ;;^UTILITY(U,$J,358.3,9089,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9089,1,3,0)
 ;;=3^Type 1 DM w/ Oth Diabetic Kidney Complications
 ;;^UTILITY(U,$J,358.3,9089,1,4,0)
 ;;=4^E10.29
 ;;^UTILITY(U,$J,358.3,9089,2)
 ;;=^5002591
 ;;^UTILITY(U,$J,358.3,9090,0)
 ;;=E10.21^^69^618^17
 ;;^UTILITY(U,$J,358.3,9090,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9090,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,9090,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,9090,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,9091,0)
 ;;=E10.22^^69^618^16
 ;;^UTILITY(U,$J,358.3,9091,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9091,1,3,0)
 ;;=3^Type 1 DM w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,9091,1,4,0)
 ;;=4^E10.22
 ;;^UTILITY(U,$J,358.3,9091,2)
 ;;=^5002590
 ;;^UTILITY(U,$J,358.3,9092,0)
 ;;=D59.3^^69^618^3
 ;;^UTILITY(U,$J,358.3,9092,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9092,1,3,0)
 ;;=3^Hemolytic-uremic syndrome
 ;;^UTILITY(U,$J,358.3,9092,1,4,0)
 ;;=4^D59.3
 ;;^UTILITY(U,$J,358.3,9092,2)
 ;;=^55823
 ;;^UTILITY(U,$J,358.3,9093,0)
 ;;=D69.0^^69^618^4
 ;;^UTILITY(U,$J,358.3,9093,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9093,1,3,0)
 ;;=3^Henoch-Schoeniein Purpura
 ;;^UTILITY(U,$J,358.3,9093,1,4,0)
 ;;=4^D69.0
 ;;^UTILITY(U,$J,358.3,9093,2)
 ;;=^5002365
 ;;^UTILITY(U,$J,358.3,9094,0)
 ;;=M30.0^^69^618^12
 ;;^UTILITY(U,$J,358.3,9094,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9094,1,3,0)
 ;;=3^Polyarteritis nodosa
 ;;^UTILITY(U,$J,358.3,9094,1,4,0)
 ;;=4^M30.0
 ;;^UTILITY(U,$J,358.3,9094,2)
 ;;=^5011738
 ;;^UTILITY(U,$J,358.3,9095,0)
 ;;=M31.0^^69^618^5
